We are live on !
Find out more
Superstring Capital Management Portfolio holdings
AUM
$200M
Turnover
47.73%
1-Year Est. Return
216.62%
This Fund
S&P 500
This Quarter Est. Return
+49.53%
1 Year Est. Return
+216.62%
3 Year Est. Return
+1,109.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$140M
AUM Growth
–
Cap. Flow
+$107M
Cap. Flow % of AUM
Cap. Flow %
76.62%
Top 10 Holdings %
Top 10 Hldgs %
70.43%
Holding
30
New
30
Increased
–
Reduced
–
Closed
–
Avg Time Held
0
years
Top 10 Avg Time Held
0
years
Top 20 Avg Time Held
0
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Immunogen
IMGN
|
+$11.9M |
| 2 |
89bio
ETNB
|
+$9.39M |
| 3 |
Ionis Pharmaceuticals
IONS
|
+$9.08M |
| 4 |
IDEAYA Biosciences
IDYA
|
+$7.5M |
| 5 |
Immunovant
IMVT
|
+$7.49M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
TDB
LAMC
Superstring Capital Management's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for Superstring Capital Management, which disclosed 30 positions worth $140M. Its ten largest holdings account for 70% of the portfolio.
Its largest position is Immunogen: 598,072 shares worth $17.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Superstring Capital Management's largest Q4 2023 buy was Immunogen: 598,072 shares worth $17.7M.
- Superstring Capital Management's ten largest holdings make up 70% of its $140M portfolio in Q4 2023.
- Superstring Capital Management disclosed 30 positions in Q4 2023, its first 13F filing on record.
Based on Superstring Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.